BioSpace News Archive

Centene Corporation (NYSE: CNC) today issued a reminder that it will release its 2020 third quarter financial results at approximately 6 a.m. (Eastern Time) on Tuesday , October 27, 2020, and host a conference call afterwards at approximately 8:30 a.m. (Eastern Time) to review the results. Michael F. Neidorff , Chairman, Presiden

410 Medical, a medical device company developing innovative products for resuscitation of critically ill patients, is pleased to announce the U.S. Food & Drug Administration (FDA) has granted 510(k) clearance for a new product in the LifeFlow family.

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) (“CNS” or the “Company”), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the central nervous system, today announced that CEO, John Climaco, will present virtually at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on Tuesday

Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that its collaborator, Roche, presented a poster with data from Part 1 of its Phase 1b study (IMscin001) evaluating atezolizumab (Tecentriq ® ) for subcutaneous administration utilizing Halozyme’s ENHANZE ® technology in patients with locally advanced or metastati

CytRx Corporation (OTCQB: CYTR), a biopharmaceutical research and development company specializing principally in oncology and neurodegenerative diseases, today highlighted that Orphayzme A/S (“Orphazyme”) announced that the U.S. Food and Drug Administration (“FDA”) has accepted, with Priority

Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD) (Nasdaq: TMDI) , a medical device company focused on the design and development of single-port robotic surgical technologies, announces that it has recently been issued two U.S. patents, increasing its global intellectual property portfolio to 58 issued patents and 84 patent applications. The Company has also received notices of allowance in 17 other patent applications

scPharmaceuticals Hosting Key Opinion Leader Call on FUROSCIX ® (furosemide) for subcutaneous administration FUROSCIX ® is currently under development for the treatment of congestion due to fluid overload in adult patients with worsening heart failure who display reduced responsiveness to oral diuretics and who do not require hospitalization Call on Tuesday, September 29, 2020 at 11am Eastern Time BURLINGTON, Mass.--( BUSINESS WIRE )-- scPha

Hepion Pharmaceuticals, Inc. announced that a study of Hepion’s CRV431 conducted by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, demonstrated positive antiviral activity against SARS coronavirus-2.

Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX:TBP.TO) (OTCQB:TBPMF), a leader in cannabinoid-derived drug discovery and development, is pleased to announce that Ms. Dale Weil and Dr. Brent Norton have been appointed to the Company’s Board of Directors and Dr. Graham Wood, Ph.D. has been appointed as Chief Operating Officer.

Proniras Corporation, a biotechnology company committed to the development of life saving therapeutic products, today announced that the company and its collaborator, Indiana University (IU) School of Medicine, have received a $12.3 million grant from the National Institute on Drug Abuse (NIDA) to support development of the company’s proprietary molecule, tezampanel, as a treatment for opioid withdrawal syndrome. Tezampanel, a